Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2008 pubmed

Antimicrobial host defense in the upper gastrointestinal tract.

Hosaka. Yoshio Y; Koslowski. Maureen M; Nuding. Sabine S; Wang. Guoxing G; Schlee. Miriam M; Schäfer. Christian C; Saigenji. Katunori K; Stange. Eduard F EF; Wehkamp. Jan J

Key Findings

  • LL‑37 is only marginally expressed in healthy upper GI tissues
  • Other antimicrobial peptides like HBD1 and inducible beta‑defensins are higher in the esophagus
  • Cationic extracts from esophagus and stomach kill E. coli but are weaker against Candida

Practical Outcomes

  • Because LL‑37 levels are low in the upper GI tract, boosting it directly may not enhance gut antimicrobial protection. Focus on supporting the more abundant peptides (e.g., HBD1, beta‑defensins) or overall mucosal health rather than LL‑37 supplementation for GI benefits.

Summary

The study looked at natural antimicrobial proteins in the upper gut and found that the peptide LL‑37 is barely present in the esophagus, stomach, and duodenum, while other defenses like HBD1 and certain defensins are more common. Even though tissue extracts killed bacteria well, they were less effective against Candida, hinting at missing antimicrobial factors.

Abstract

With the exception of fungi, microbial infections are rare in the oesophagus. Herein, we aimed to systematically assess the distribution and quantity of different antimicrobial host factors as well as, for the first time, functional mucosal antimicrobial activity in the upper gastrointestinal tract. We investigated biopsies from the healthy oesophagus, three different locations in the stomach and the duodenum in a total of 12 individuals. Using real-time PCR with external standards, we compared absolute expression of mRNA encoding antimicrobial peptides including defensins, cathelicidin, bactericidal/permeability-increasing protein, psoriasin, and elafin. In addition, we performed immunostaining for human-beta-defensin-1 (HBD1), elafin, and psoriasin. To test functional relevance, we assessed antimicrobial as well as antifungal activity of cationic extracts from biopsies against E. coli ATCC 25922 and a clinical isolate of Candida albicans. In contrast to HBD1 which was similarly expressed in all tissues, inducible beta-defensins in the healthy oesophagus were much higher compared with the stomach and duodenum (for HBD2-4: P<0.01). In addition, the antiproteases elafin and psoriasin were also predominantly expressed in the oesophagus (P<0.005). In contrast, LL-37 and bactericidal/permeability-increasing protein were only marginally expressed. Cationic tissue extracts from both the oesophagus as well as the stomach showed potent antibacterial activity against E. coli. Consistent with susceptibility to Candida infection, the esophageal extracts exhibited a weaker activity against C. albicans (P=0.026). Despite dominant expression of antimicrobial host peptides, oesophageal tissue shows a weakened potency to kill C. albicans. These data suggest an important role of yet unknown antimicrobial molecules.

Study Information

Provider

pubmed

Year

2008

DOI

10.1097/meg.0b013e3283052ddb